JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2005; 46:1812-1819, doi:10.1016/j.jacc.2005.06.079 (Published online 18 October 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leon, M. B.
Right arrow Articles by Kuntz, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leon, M. B.
Right arrow Articles by Kuntz, R. E.

A Blinded, Randomized, Placebo-Controlled Trial of Percutaneous Laser Myocardial Revascularization to Improve Angina Symptoms in Patients With Severe Coronary Disease

Martin B. Leon, MD*, Ran Kornowski, MD, William E. Downey, MD, Giora Weisz, MD, Donald S. Baim, MD, Robert O. Bonow, MD, Robert C. Hendel, MD, David J. Cohen, MD, MSc, Ernest Gervino, DSc, Roger Laham, MD, Nicholas J. Lembo, MD, Jeffrey W. Moses, MD and Richard E. Kuntz, MD, MSc

Cardiovascular Research Foundation, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, New York.



View larger version (18K):

[in a new window]
  		Figure 1 Freedom from major adverse cardiac events (MACE) from the index procedure to 12 months. Comparisons between groups at 12 months were not statistically significant.

 


View larger version (24K):

[in a new window]
  		Figure 2 Exercise duration(s) at baseline, at 6 months, and at 12 months of follow-up and the change in exercise duration between baseline and 6 months. The change in exercise duration was maintained at 12 months. All comparisons between groups were not statistically significant.

 


View larger version (18K):

[in a new window]
  		Figure 3 Canadian Cardiovascular Society angina class III or IV at baseline and 6- and 12-month follow-up. All comparisons between groups were not statistically significant.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.